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The Importance of Protocol
Design and Data Reporting to
Research on Endocrine
Disruption
Several recent articles have discussed the
doubts expressed by some scientists regarding
the validity of endocrine disruption studies
conducted by industrial scientists or spon-
sored by the chemical industry (1-3). The
last of these articles (3) recounted personal
attacks made on the integrity ofStephen Safe
ofTexas A&M University.
It is in the nature ofany new branch of
toxicology that, at least initially, adverse
effects may be discovered for chemicals by
those academic laboratories working in the
new area. The chemical industry is then left
to confirm and extend the findings ofothers.
Such confirmatory studies are usually neces-
sary because the initial publications often
describe the results oflimited or unreplicated
experiments (4). The articles mentioned
above (1-3) concerned the prospect that
repeat studies conducted by or sponsored by
the chemical industry are designed in order
not to confirm the original observation. We
wish to discuss the complementary concern
that many new findings in this area are either
inadequately described or are based on data
derived using inadequate test protocols. This
makes it difficult to conduct faithful repeat
experiments, however well-motivated the
responsible scientists are.
We recently decided to confirm and
extend adverse endocrine toxicities reported
for nonylphenol (NP) and bisphenol-A
(BPA). For both ofthese chemicals, we expe-
rienced problems when attempting to design
repeat experiments due to inadequacies ofthe
original publications. These inadequacies may
seem to be relatively minor, but when the
outcomes ofthe repeat experiments are likely
to bechallenged, theybecome important.
Three influential papers using the Noble
rat have been published by Colerangle and
Roy over the past 4 years (5-7). The papers in
question report the results of implanting the
estrogens estrone, diethylstilbestrol (DES),
NP, or BPA into Noble rats and monitoring
the consequent changes in cell growth in the
mammary gland. Either pellets or mini-
pumps were used to deliver the test chemicals
over 11 days. In each case growth of the
mammary gland was reported. A significant
aspect ofthese results is that estrogenic effects
were found for NP and BPA at much lower
dose levels than would have been expected
based on the results of earlier studies (8-11),
in particular, rat uterotrophic assays conduct-
ed using three dailyadministrations ofthe test
chemicals. To resolve the uncertainties created
by this apparent difference in assay sensitivi-
ties, we embarked on full repeats ofthe DES
and NP Noble rat mammary gland assays
(5-7). We also conducted rat uterotrophic
assays utilizing the dosing protocol used by
Colerangle and Roy [the test compound
administered over 11 days via subcutaneously
implanted mini-pumps (5-7)] and multiple
strains ofrats, including the Noble strain.
The following inadequacies of the three
published studies in Noble rats have compli-
cated their interpretation and the design of
our own studies (5-7).
In the first study (5), DES was adminis-
tered over 11 days as a subcutaneously
implanted pellet. Cell labeling indices and
growth fractions ofmammarygland cells were
determined using the methods ofFoley et al.
(12). DES was reported to increase the label-
ing index from 11% (controls) to 71%.
Recalculation (12) of these indices from the
primarydata presented (5) gavevalues of11%
and 21% for controls and DES, respectively.
Likewise, the growth fractions were reported
to be 21% for controls and 158% for the
DES animals; recalculation (12) from the pri-
mary data presented (5) gave values of 21%
and 47%, respectively. The estrone figures
were also in error. These errors, which have
not been formally corrected by the authors,
make it difficult to be certain of the magni-
tude of the effects expected in our repeat
experiments. Subsequent data from these
authors (6,7) appear to have been correctly
calculated based on cell number estimates
derived from the bar charts presented.
In the second and third papers (6,7), the
activities of NP and BPA in the mammary
gland ofNoble rats were compared to that of
DES. DES was shown as a positive control
agent in both of these papers, and in each
case the test data were identical to those
reported to the original study (5), including
use of the incorrect labeling indices and
growth fractions. The wrong impression was
thereby given that the DES study had been
replicated three times. Further, in the BPA
paper (7), the DES is described as being
administered via a mini-pump, whereas in
the initial paper (5) it is reported to have
been given as a pellet. No experimental
details were provided for the administration
of DES in the NP paper (6). Thus, after
three separate publications, the test data for
DES have apparentlyyet to be replicated.
Despite being published separately and a
year apart, the vehicle control data for the
NP (6) and the BPA (7) studies are the same
in each paper and different from those in the
original study (5). Either the data for NP and
BPA were derived from a single study that
was then published in two isolated parts or a
vehicle control group was absent from one of
the two studies (6,7). This created an unac-
ceptable level ofuncertainty.
Thus, while attempting to repeat these
significant new findings in the Noble rat, we
were presented with uncertainties in the orig-
inal papers that could have been regarded as
intentional had they occurred in our own
(industrial) studies.
Nagel et al. (13) reported that BPA
increased the weight of the prostate gland in
mature CF-1 mice exposed in utero. In a sub-
sequent paper from the same laboratory, vom
Saal et al. (14) reported the induction ofsimi-
lar effects by DES. When designing a repeat
ofthe CF-1 mouse experiment with BPA, we
decided to include DES as a positive control
chemical, despite the absence ofsuch a con-
trol in the original BPA study (13). However,
we were presented with a problem: the BPA
animals described by Nagel et al. (13) were
terminated at 6 months and the DES animals
described by vom Saal et al. (14) were termi-
nated at 8 months. No explanation for this
difference in test protocol was given. It was
therefore impossible to mount a faithful con-
current report of the BPA and DES experi-
ments; thus, we decided to terminate both of
our groups at 6 months. However, that means
that we will not have faithfully repeated the
original study on DES.
Another aspect of the study by Nagel et
al. (13) caused us concern. In that study, two
control groups were used: a vehicle control
group and a group of animals that were not
handled throughout the study. It was stated
(13) that these two control groups gave simi-
lar data (not shown) and that they were
therefore combined into a single, larger con-
trol group and used as such for the subse-
quent statistical analysis ofthe BPA test data.
That represents bad statistical practice. We
decided to include two such control groups
in our own experiment and to maintain their
separate identities during the statistical analy-
sis ofour data. Each ofthese small changes in
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our experimentation could eventually be used
to discredit our findings, should they happen
not to agree with the original observations.
It seems important that all experiments in
the rapidly expanding area of endocrine dis-
ruption toxicology should be carefully
designed and fully reported. The use ofcon-
current positive and negative control groups
also seems to be prudent. These needs are
independent of who conducts or sponsors
studies. Good science is good science. Finally,
it should be noted that the onlyformal retrac-
tion ofendocrine disruption data currently
encountered derived from an academic labo-
ratory (15), a salutary counterbalance to the
assertions that stimulated this letter (1-3).
JohnAshby
Jenny Odum
Zeneca Central Toxicology Laboratory
Alderley Park, Cheshire, United Kingdom
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Response
In a paper we published last year (1), we
described biological effects in vivo on the
rodent prostate caused by fetal exposure to
very low doses of the environmental estrogen
bisphenol A; this low-dose effect was predicted
by a new in vitro assay. For the in vivo end
point of prostate enlargement, the effect pro-
duced by bisphenol A mimicked the effect of
fetal exposure to low doses ofthe natural and
synthetic estrogens estradiol and DES, which
were reported in another paper (2). Fetuses
were exposed to bisphenol A by feeding preg-
nant female mice at average maternal doses of
2 and 20 sg/kg maternal bodyweight per day
(2 and 20 ppb); these exposure levels produced
enlarged prostates measured in subsequent
adulthood. Our conclusion was that these
doses of bisphenol A, up to 25,000 times
lower than the previously reported NOAEL
(no observed adverse effect level) for bisphenol
A (3), were near andwithin reported ranges of
current human exposures from different
sources of this chemical (4,5). Three subse-
quent reports by two other groups have con-
firmed our finding ofhigh estrogenic bioactiv-
ity of bisphenol A in vivo using end points
(pituitary and mammary gland responses) that
were different from ours (6-il.
We find perplexing the statement ofAshby
and Odum that "many new findings in this
area are either inadequately described or are
based on inadequate test protocols. This makes
it difficult to conduct faithful repeat experi-
ments." The information that went into our
experimental design is based on more than 50
years of combined experience in hormone
action and control ofdevelopment. It is impos-
sible to put all ofthis information in any one
paper, and experimental details that have been
published previously are typically not repeated
[for example, see (9,10)]. For these reasons,
when we are interested in replicating an experi-
ment, we contact the original authors, and
other scientists have often contacted us for the
same reason. Forexample, Ashbyhas contacted
us on numerous occasions concernig experi-
mental procedures for the replication of our
studies. In addition, we recendy ran a training
session forlaboratorypersonnel from a contract
laboratory hired by the Society of the Plastics
Industry to replicate our study with bisphenol
A. Given this degree ofcooperation withAshby
and others associated with the chemical indus-
try, which is also true for Richard Sharpe (11),
we are puzzled as to why Ashby and Odum
would make the above statement. Considering
the many questions they raise above in under-
standing the procedures ofColerangle and Roy
(8, we would hope that they would also have
contactedtheoriginalauthors in thatstudy.
Ashby and Odum also raised tWO specific
questions about our studies (1,2). The first
question concerned examination of prostate
weight at 8 months ofage in one study with
prenatal exposure to estradiol and DES,
while bisphenol A-exposed animals were
examined at 6 months old of age. We had
conducted a preliminary study comparing
prostate weight in control CF-1 male mice
(five to nine males/group) at 6, 7, 8, 9.5, and
12.5 months of age, which resulted in the
following mean (± standard error) prostate
weights (in milligrams): 42.1 ± 2.5, 40.8 ±
2.7, 45.1 ± 3.8, 41.1 ± 2.8, and 61.3 ± 2.8,
respectively. These unpublished findings
showed that between 9 and 12 months of
age, male CF-1 mice experienced asignificant
increase in prostate weight, but between 6
and 9 months ofage, there was no significant
difference in prostate weight. We had initial-
ly waited until males were 8 months old to
examine effects of prenatal treatment with
estradiol and DES on the prostate due to
concern that effects might only be seen in
middle age (12). However, we have sought to
reduce the age at organ collection in these
studies to reduce costs. Relative to control
males, an increase in prostate weight was seen
at 6 months ofage in the bisphenol A study
and, more recently, was also found in 50-
day-old CF-1 male mice exposed prenatally
to lowdoses ofethinyl estradiol (13).
The second technical question concerned
the combination ofvehide control and unhan-
dled control animals into a single control
group in our studies. In all ofour experiments
we conduct an initial analysis just with these
two control groups. In every study that we
have conducted, this initial analysis has
revealed no statistical difference between the
two groups (the F value was 0.7 andp>O.4 for
this comparison in the bisphenol A study on
prostate weight); these animals were then com-
bined into one control group for comparison
to chemical treatment groups. Ashby and
Odum state, "that represents bad statistical
practice." However, an initial comparison of
multiple control groups is a common and
appropriate procedure, although from some
perspectives, there would be a decided advan-
tage in not taking this approach. Specifically,
the F ratio in analysis ofvariance is calculated
as the product ofvariation between groups
divided byvariation within groups. Thegreater
the number ofgroups with the same mean that
are placed into an analysis of variance, the
greater the reduction in the F ratio, and there-
fore thegreater theprobability offailingto find
statistical significance. The procedure recom-
mended by Ashby and Odum would thus
increase the likelihood of falsely concluding
that the test chemicalhad no effect.
The initial point made by Ashby and
Odum involves the discovery ofadverse effects
for chemicals by academic laboratories and that
the chemical industry is left tO confirm unrepli-
cated findings. It seems inappropriate to coin-
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